Abstract:BACKGROUND Idiopathic pulmonary fibrosis (IPF) is classified under fibrotic interstitial pneumonia, characterized by a chronic and progressive course. The predominant clinical features of IPF include dyspnea and pulmonary dysfunction. AIM To assess the effects of pirfenidone in the early treatment of IPF on lung function in patients. METHODS A retrospective analysis was performed on 113 patients with IPF who were treated in our hospital from November 2017 to January 2023. These patients were divided into two groups: control group (n = 53) and observation group (n = 60). In the control group, patients received routine therapy in combination with methylprednisolone tablets, while those in the observation group received routine therapy together with pirfenidone. After applying these distinct treatment approaches to the two groups, we assessed several parameters, including the overall effectiveness of clinical therapy, the occurrence of adverse reactions (e.g., nausea, vomiting, and anorexia), symptom severity scores, pulmonary function index levels, inflammatory marker levels, and the 6-min walk distance before and after treatment in both groups. RESULTS The observation group exhibited significantly higher rates than the control group after therapy, with a clear distinction (P < 0.05). After treatment, the observation group experienced significantly fewer adverse reactions than the control group, with a noticeable difference (P < 0.05). When analyzing the symptom severity scores between the two groups of patients after treatment, the observation group had significantly lower scores than the control group, with a distinct difference (P < 0.05). When comparing the pulmonary function index levels between the two groups of patients after therapy, the observation group displayed significantly higher levels than the control group, with a noticeable difference (P < 0.05). Evaluating the inflammatory marker data (C-reactive protein, interleukin-2 [IL-2], and IL-8) between the two groups of patients after therapy, the observation group exhibited significantly lower levels than the control group, with significant disparities (P < 0.05). Comparison of the 6-min walking distance data between the two groups of patients after treatment showed that the observation group achieved significantly greater distances than the control group, with a marked difference (P < 0.05). CONCLUSION Prompt initiation of pirfenidone treatment in individuals diagnosed with IPF can enhance pulmonary function, elevate inflammatory factor levels, and increase the distance covered in the 6-min walk test. This intervention is conducive to effectively decreasing the occurrence of adverse reactions in patients.

Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Perspectives of PDE Inhibitor on Treating Idiopathic Pulmonary Fibrosis

The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

Emerging Opportunities to Treat Idiopathic Pulmonary Fibrosis: Design, Discovery, and Optimizations of Small-Molecule Drugs Targeting Fibrogenic Pathways.

Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis

Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential

[Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment]

[Idiopathic pulmonary fibrosis: recent diagnostic and therapeutic advances]

Advances of Targets and Therapeutic Drugs for Idiopathic Pulmonary Fibrosis

Novel drug targets for idiopathic pulmonary fibrosis

Study on the efficacy of early treatment with pirfenidone on the lung function of patients with idiopathic pulmonary fibrosis

Evidence from recent clinical trials in fibrotic interstitial lung diseases

Targeting PI3K/AKT Signaling for Treatment of Idiopathic Pulmonary Fibrosis

Updates in pharmacotherapy for idiopathic pulmonary fibrosis

Inhaled Nanoparticles for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Honeycomb Cyst and Alveoli Interstitium Remodeling